How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China [Yahoo! Finance]
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: Yahoo! Finance
bipolar candidate RAP-219 across Greater China, in a deal including a US$20 million upfront payment and up to approximately US$308 million in potential milestones plus tiered royalties. The agreement effectively turns Greater China into a major development hub for RAP-219, adding Phase 3 trial sites in China while allowing Rapport to retain rights in the rest of the world and benefit from Tenacia's regional execution. We'll now explore how this RAP-219 partnership, including the upfront cash and potential milestones, shapes Rapport Therapeutics' investment narrative. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality What Is Rapport Therapeutics' Investment Narrative? To own Rapport Therapeutics, you really have to believe in RAP-219 as a cornerstone asset and in management's ability to finance a broad neuroscience pipeline without overwhelming shareholders. The Tenacia deal slots neatly into that story: US$20 mil
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics (RAPP) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RAPP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hMarketBeat
- Rapport Therapeutics (RAPP) had its price target raised by Wells Fargo & Company from $43.00 to $46.00. They now have an "overweight" rating on the stock.MarketBeat
- Rapport Therapeutics (RAPP) had its "market outperform" rating reaffirmed by Citigroup Inc..MarketBeat
- Rapport Therapeutics GAAP EPS of -$0.72 misses by $0.03 [Seeking Alpha]Seeking Alpha
- Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
RAPP
Earnings
- 3/10/26 - Miss
RAPP
Sec Filings
- 3/10/26 - Form S-3ASR
- 3/10/26 - Form S-8
- 3/10/26 - Form 10-K
- RAPP's page on the SEC website